Aegerion Pharmaceuticals, Inc. – Rare-Disease Specialist Succumbs to Multiple Challenges and Files Chapter 11, Expected to Emerge as Wholly-Owned Subidiary of Amryt Pharma Plc

May 20, 2019 − Aegerion Pharmaceuticals, Inc and one affiliated Debtor ("Aegerion" or the "Debtors") filed for Chapter 11 protection with the U.S. Bankruptcy Court in the Southern District of New York, lead case number 19-11632. The Company, a wholly-owned subsidiary of Novelion Therapeutics Inc. ("Novelion," NASDAQ: NVLN), a biopharmaceutical dedicated to developing and commercializing prescription…